Skip to content

Advancing Next-Generation Psychedelic Therapeutics through Selective 5-HT2A Activation, Precision Aerosol Delivery, and Optimized 5-MeO-DMT Treatment Paradigms

Anna C. Renner, Robert B. Kargbo

ACS Medicinal Chemistry Letters July 10, 2026 DOI: 10.1021/acsmedchemlett.6c00364 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Population Not applicable
Topics 5-MeO-DMT DMT Serotonin
Keywords Aerosol Precision medicine Nanotechnology
Key findings Recent patent applications disclose selective 5-HT2A receptor activators, precision aerosol delivery technologies for psychedelic compounds, and structured 5-MeO-DMT treatment regimens for depression, indicating a convergence toward scalable and safer neuropsychiatric therapies.

Abstract

High Resolution Image Download MS PowerPoint Slide The psychedelic therapeutics field continues to evolve beyond classical hallucinogens toward integrated treatment platforms that combine optimized pharmacology, drug delivery, and clinical implementation. Recent patent applications disclose selective 5-HT2A receptor activators, precision aerosol delivery technologies for psychedelic compounds, and structured 5-MeO-DMT treatment regimens for depression. Together, these innovations illustrate a convergence toward scalable, safer, and clinically practical neuropsychiatric therapies that may reshape the future of serotonergic medicine.

In the evidence

This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.

  • State of the evidence: 5-MeO-DMT Supports

    The review argues that recent patent applications disclose selective 5-HT2A receptor activators, precision aerosol delivery technologies, and structured 5-MeO-DMT treatment regimens for depression, indicating a convergence toward scalable and safer neuropsychiatric therapies.

    Synthesized

Comparable studies

Other narrative reviews on 5-MeO-DMT, most cited first.

Study Year Design Participants
Neuropharmacology of N,N-dimethyltryptamine 2016 Review
N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function Humans and animals (general) 2018 Review
Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Humans (pharmacokinetics) 2010 Review
Dark Classics in Chemical Neuroscience:N,N-Dimethyltryptamine (DMT) 2018 Review
A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity. 2013 Review

Citations in the library

Cites 5

Related reading

Explore topics

5-MeO-DMT DMT Serotonin Depression Psychedelic-assisted therapy